Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM, Colon Cancer
Interventions: LTZ-232; Drug
Lead sponsor: LTZ Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Catheterization, Peripheral
Interventions: BOA(R)-Constricting IV Band, Standard elastic constricting band; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Raltegravir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 12
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 7 more

Conditions: Solid Tumor, Hematological Malignancies
Interventions: Belinostat, Atazanavir; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Cushings Disease
Interventions: Pasireotide; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Blood Pressure Monitoring, Blood Pressure
Interventions: Chest Worn Blood Pressure Monitor; Device
Lead sponsor: Perin Health Devices; Industry
Eligibility: 22 Years to 90 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Multiple Myeloma
Interventions: ACY-1215, lenalidomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more

Conditions: Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC), Gastric Cancer (GC), Esophageal Cancer (EC), Head and Neck Squamous Cell Cancer (HNSCC)
Interventions: SKL35501, SKL35502; Drug · Diagnostic Test
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Glen Burnie, Maryland • Pittsburgh, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Idiopathic Hypersomnia, Narcolepsy
Interventions: JZP258 (XYWAV); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more

Conditions: Prostate Cancer, Adenocarcinoma
Interventions: Hypofractionated, image-guided, intensity-modulated external beam radiation; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 7
States / cities: Commack, New York • Harrison, New York • New York, New York + 4 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 16
States / cities: Murrieta, California • Rialto, California • Ventura, California + 13 more

Conditions: Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
Interventions: Zopapogene imadenovec (Zopa); Drug
Lead sponsor: Precigen, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio

Conditions: Pancreatic Cyst, Pancreas Disease
Interventions: Bio-Specimen Collection; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions: Povetacicept; Drug
Lead sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more

Conditions: Skin Cancer, Mohs Micrographic Surgery, Interpolated Flap Repair
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 1 Year to 99 Years
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Brain Tumor
Interventions: ABT 510; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Systemic Lupos Erythematosus, SLE
Interventions: BIIB068, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Pancreas Cancer
Interventions: L-DOS47, Doxorubicin; Biological · Drug
Lead sponsor: Helix BioPharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Morristown, New Jersey • Milwaukee, Wisconsin

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon IR, Dimebon Transdermal; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions: MT-8421, Nivolumab; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more

Conditions: Body Composition, Executive Functioning, Temperament
Interventions: Observation; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Months to 24 Months
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Progressive Multiple Sclerosis
Interventions: KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU); Biological · Drug
Lead sponsor: Bruce Cree; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

Effectiveness Study of the BOA(R)-Constricting IV Band

Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Noninvasive Blood Pressure Validation Study

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

Zopa Retreatment and Vector Shedding in Adults With RRP

Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Early Genetic and Environmental Influences on Eating - The Baylor Infant Twins Study

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis